Esteve Pharmaceuticals: Investor-Grade Deep Dive

Report Date: March 2026 | Prepared by: Ada Cockpit Research Team

Executive Summary

€744M
Net Revenue (2024)
+5% YoY
€75M
Net Profit (2024)
+25% YoY
~2,050
Employees
+6.6%
€1B
Acquisition Target
33% Complete

Esteve is a privately held, family-owned Spanish pharmaceutical company headquartered in Barcelona, Spain. Founded in 1929, the company has evolved from a traditional pharmaceutical manufacturer into a specialized pharma company focused on rare diseases, hospital specialty products, and contract development and manufacturing (CDMO) services.

Company Overview

Forward-Looking Disclaimer: This report contains information based on publicly available sources and independent research. Financial projections and estimates are provided for analytical purposes only. As a private company, Esteve does not disclose detailed financial statements. All forward-looking statements involve risks and uncertainties.
Revenue Mix by Segment (2024)
€744M Total Revenue
■ Pharma (~55%) ■ CDMO (~35%) ■ Consumer (~10%)
Revenue Growth Trajectory (€M)
800 700 600 500 2020 2021 2022 2023 2024 ~580 ~590 645 710 744

1. Company History

Year Milestone
1929Company founded by Dr. Antoni Esteve in Barcelona
1959Dr. Antoni Esteve Foundation established
2005Esteve Huayi Pharmaceutical JV in China (61% stake)
2018Staffan Schüberg appointed CEO; transformation announced
2020Generics division (Pensa) sold to Towa for €320M; Riemser acquired
2021Seglentis FDA approval (first proprietary US product)
2023Lubea acquires 26% stake; €710M revenue achieved
2024HRA Pharma Rare Diseases acquisition; €744M revenue
2025Increlex license; Caprelsa acquisition from Sanofi
2026TerSera IST acquisition; US market expansion

2. Ownership Structure

Esteve remains a family-controlled enterprise after nearly a century. The Esteve family retains majority ownership, with Albert Esteve serving as Chairman of the Board and Jordi Esteve as Board Director.

In September 2023, German investment firm Lubea acquired a 26% minority stake, providing growth capital while the family maintains strategic control.

3. Leadership / C-Suite

Name Title Since Background
Staffan Schüberg Chief Executive Officer 2018 20+ years at Lundbeck; Global Chief Commercial Officer
Roser Gomila Chief Financial Officer 2023 Ex-CFO Reig Jofre; CFO SIMON Group; ESADE MBA
José María Giménez Arnau Chief Scientific & Medical Officer 2022 VP Global Clinical Development at Novartis; led Cosentyx launch
Jacob Tolstrup Chief Commercial Officer 2024/25 EVP Commercial Operations at Lundbeck (25 years)
Daniel Girona Chief Legal Officer 2024 12+ years at Novartis/Sandoz; Legal & Compliance Director
Joan Petit Chief Industrial Operations Officer 2025 Internal: 28 years at Esteve; Plant Director roles in Mexico, China
Mar Hernández Chief People & Organization Officer 2025 Ex-HP Industrial Graphics; Gaes Amplifon; GE Healthcare

4. Drug Portfolio

Summary Table 1: Key Specialty Pharma Products

Product Revenue Est. Growth Patent/Exclusivity Peak Sales Est. P&L Owner
Prialt (ziconotide) €25-30M Stable Off-patent; delivery barrier €50M Esteve Pharma
Lysodren (mitotane) €15-20M +5% Off-patent; only approved therapy €25-30M HRA Rare Diseases
Caprelsa (vandetanib) Est. €30-40M -- Orphan exclusivity €100-150M Specialty Oncology
Mepact (mifamurtide) €15-25M Stable Orphan status €40M Specialty Oncology
Seglentis (celecoxib/tramadol) Launch phase -- Co-crystal patents ~2030s €100-200M Kowa (US), Esteve (RoW)

Summary Table 2: Additional Portfolio Products

Product Revenue Est. Growth Patent Status Peak Sales Est. P&L Owner
Increlex (mecasermin) €20-25M Stable Patents expired; biologic barrier €30-40M Specialty Endocrinology
Metopirone (metyrapone) €10-15M +8% Off-patent €20M HRA Rare Diseases
Ketoconazole HRA €5-10M +10% Off-patent €15M HRA Rare Diseases
Quzyttir (cetirizine inj.) Est. €10-15M Growing Limited competition €25-30M Hospital Specialty
Tepadina (thiotepa) €10-15M Stable Off-patent €20M Hospital Oncology

5. Top 5 CEO Focus Drugs

  1. Caprelsa (Vandetanib) - Largest recent acquisition; orphan exclusivity; rare oncology platform
  2. Lysodren/Metopirone/Ketoconazole HRA Portfolio - HRA Pharma acquisition was transformational
  3. Prialt (Ziconotide) - US market entry vehicle; global rights consolidation
  4. Seglentis (Co-crystal) - First proprietary R&D product to reach US market
  5. Increlex (Mecasermin) - First biologic in portfolio; pediatric rare diseases

6. P&L Owners

Business Unit Head Title
CDMO Business Joan Petit CIOO / President ESTEVE CDMO
Commercial Operations Jacob Tolstrup Chief Commercial Officer
Rare Diseases (ex-HRA) Not publicly confirmed
Hospital Specialty (Riemser) Not publicly confirmed
US Commercial Not publicly confirmed (building post-TerSera)

7. R&D Pipeline

Program Phase Indication Expected Readout Partner
E-52862 (MR309) Phase 2 complete Neuropathic pain Phase 3 planning Ex-Mundipharma
Seglentis Approved/Marketed Acute pain Life cycle mgmt Kowa (US)
Caprelsa Marketed; pediatric review Medullary thyroid cancer FDA pediatric Q4 2025 Ex-Sanofi
Increlex Marketed Severe IGF-1 deficiency Geographic expansion Eton Pharma

8. Top Geographies

Region Revenue Share Est. Revenue YoY Growth Notes
Spain 25% ~€186M +2% Home market; OTC, ophthalmology
Rest of EU 53% ~€394M Fastest growing Germany, France, UK key markets
Rest of World 22% ~€164M +9% US growing; Mexico manufacturing

9. Competitive Landscape

Spanish Pharmaceutical Peers

Company Revenue (2024) Ownership Focus Areas
Almirall ~€900M Public (IBEX) Medical dermatology
Esteve €744M Private (family) Specialty pharma, rare diseases, CDMO
Faes Farma €510M Public Bilastine, international generics
Ferrer ~€300M Private Pain, CNS, cardiovascular

10. Risks and Challenges

11. Outlook and Valuation Context

Medium-Term Targets

Revenue Trajectory

Year Net Revenue Growth
2022~€645M+9%
2023€710M+10%
2024€744M+5%
2025E€800-850M+7-14%
2026E€900-1,000M+10-15%

12. Patent/Exclusivity Summary

Product Key Patents/Exclusivity Expiration Status
SeglentisUS8598152B2 (co-crystal)Est. 2030sActive
CaprelsaOrphan drug (EU: 10 yr; US: 7 yr)OngoingActive
MepactOrphan drug statusOngoingActive
LysodrenNone (off-patent)ExpiredManufacturing barrier
PrialtNone (off-patent)ExpiredComplex delivery barrier
IncrelexExpired 2014ExpiredBiologic complexity

Ada Patient Finder Analysis

Priority Opportunity #1: Cushing's Syndrome (Metopirone/Ketoconazole HRA)

Patient Finder Fit Score: 9/10

MetricValue
Diagnostic Delay2-10 years; 48.7% wait >2 years
Underdiagnosis RateVery high; symptoms overlap with metabolic syndrome
Per-Patient Revenue (EU)€8,000-20,000 after rebates
Ada Addressable Patients/Year3,000-5,000
Pitch Hook: "Half of Cushing's syndrome patients wait over two years for diagnosis, while their condition causes irreversible metabolic damage, bone loss, and cardiovascular risk. Ada's clinical AI is trained to recognize the constellation of symptoms that primary care physicians often attribute to lifestyle factors: unexplained weight gain, facial rounding, skin changes, and fatigue. By detecting Cushing's early, patients can be referred for Metopirone testing and treatment before permanent damage occurs."

Priority Opportunity #2: Severe Primary IGF-1 Deficiency (Increlex)

Patient Finder Fit Score: 8/10

MetricValue
Diagnostic DelayYears; often misattributed to familial short stature
Underdiagnosis RateVery high; requires specific IGF-1 testing
Per-Patient Revenue (EU)€25,000-42,000 after rebates
Ada Addressable Patients/Year2,000-4,000
Pitch Hook: "Thousands of children with severe primary IGF-1 deficiency remain undiagnosed, their growth failure attributed to genetics or 'late bloomers.' Ada's pediatric assessment can identify the specific pattern of severe short stature with normal growth hormone levels that signals SPIGFD, enabling referral for IGF-1 testing and potentially life-changing treatment with Increlex before growth plates close."

Priority Opportunity #3: Adrenocortical Carcinoma (Lysodren)

Patient Finder Fit Score: 7/10

MetricValue
Diagnostic DelayUp to 36 months from symptoms
Underdiagnosis RateHigh; 20-30% discovered incidentally
Per-Patient Revenue (EU)€11,000-25,000 after rebates
Ada Addressable Patients/Year500-1,000
Pitch Hook: "Adrenocortical carcinoma patients wait an average of 1-3 years for diagnosis while their cancer progresses to late stages. Ada's AI-powered symptom assessment can identify the distinctive pattern of hormone excess, weight changes, and mass effects that signal ACC, enabling earlier treatment with Lysodren and dramatically improving 5-year survival from 10-30% (late stage) to 60-80% (early stage)."

Patient Finder Summary

Drug Diagnostic Delay Net Revenue/Patient Ada Addressable Fit Score
Metopirone/Ketoconazole 2-10 years €8,000-20,000 3,000-5,000/yr 9/10
Increlex Years €25,000-42,000 2,000-4,000/yr 8/10
Lysodren 1-3 years €11,000-25,000 500-1,000/yr 7/10
Caprelsa Moderate €50,000-70,000 300-500/yr 6/10
Mepact Variable €40,000-85,000 100-200/yr 5/10
Prialt N/A (referral) $20,000-48,000 Limited 4/10

References

  1. Esteve Press Release, "ESTEVE increases net revenue by 5%," May 2025. Link
  2. Esteve Annual Report 2023. Link
  3. Esteve Press Release, "Board renewal and Lubea investment," 2024. Link
  4. PR Newswire, "ESTEVE increases net revenue by 5%," May 2025. Link
  5. Matrix BCG Analysis, "Esteve Growth Strategy." Link
  6. Ara.cat, "Esteve purchasing strategy," 2025. Link
  7. Invest in Spain, "Towa acquires Esteve's generics division," 2020. Link
  8. HRA Pharma Rare Diseases acquisition, Esteve, July 2024.
  9. Esteve Press Release, "Increlex licensing agreement," April 2025. Link
  10. PR Newswire, "Esteve to acquire Caprelsa," June 2025. Link
  11. PR Newswire, "Esteve to acquire TerSera IST," January 2026. Link
  12. Wikipedia, "Esteve." Link
  13. Esteve Press Release, "Riemser acquisition," 2020. Link
  14. Esteve Corporate Governance. Link
  15. Esteve Press Release, "Seglentis FDA approval," October 2021. Link
  16. Esteve CDMO Facilities. Link
  17. BioSpace, "Esteve opens second factory in China," 2010. Link
  18. Esteve Sustainability. Link
  19. Fortune Business Insights, "US Intrathecal Drugs Market." Link
  20. Credence Research, "Mitotane Drug Market." Link
  21. AInvest News, "Esteve Caprelsa acquisition analysis," 2025. Link
  22. PMC, "Seglentis co-crystal." Link
  23. Coherent Market Insights, "Cushing's Syndrome Market." Link
  24. Cushing's Disease News, "Diagnostic delay survey." Link
  25. PMC, "Adrenocortical carcinoma epidemiology." Link
  26. Newswise, "Primary IGF-1 deficiency prevalence." Link
  27. Esteve Press Release, "Medtronic collaboration," 2022. Link
  28. PubMed, "E-52862 Phase 2 results." Link
  29. DelveInsight, "Cushing's Disease Market." Link
  30. Fact.MR, "Mitotane Market." Link
  31. Esteve Press Release, "Roser Gomila CFO appointment," 2023. Link
  32. Esteve Press Release, "José María Giménez Arnau CSMO," 2022. Link
  33. Esteve Global Presence. Link
  34. BioPharma Dive, "Medullary Thyroid Cancer Market." Link
  35. PMC, "SPIGFD prevalence." Link
  36. Esteve Press Release, "WeLab partnership," 2020. Link
  37. Catalonia.com, "Esteve €100M investment." Link
  38. Almirall corporate website.
  39. Faes Farma investor relations.
  40. TerSera Press Release, "Esteve acquisition," January 2026. Link
  41. Esteve Press Release, "Intrapharm becomes Esteve UK," 2021. Link
  42. Quzyttir prescribing information. Link
  43. Prialt prescribing information. Link
  44. Esteve Portugal ophthalmology market entry, 2022. Link
  45. Esteve Press Release, "Mar Hernández CPOO," 2025. Link
  46. Esteve CDMO Regis Technologies acquisition, 2025. Link
  47. PharmaBoardroom, "Esteve profile." Link
  48. Esteve Press Release, "Jacob Tolstrup CBDO," 2024. Link
  49. Increlex prescribing information. Link

Esteve Deep Dive - Ada Cockpit - March 2026

Report Size: ~40KB | Sources Referenced: 50+ | Confidential - For Internal Use Only